TSN222 in Subjects With Advanced Solid Tumors or Lymphomas

Clinical trial NCT05842785 · UNKNOWN

Trial details

NCT number: NCT05842785
Sponsor: Tyligand Bioscience (Shanghai) Limited
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma

Start date: 2023-07-26
Primary completion: 2025-06-01
Enrollment: 162

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.